Anaplastic Ependymal Tumor

Anaplastic ependymal tumor is an older label that referred to a fast-growing (grade 3) ependymoma—a tumor that starts from ependymal cells, the cells lining the fluid-filled spaces (ventricles) in the brain and the central canal in the spinal cord. In 2021, the World Health Organization (WHO) changed how ependymomas are named and graded. Instead of calling something “anaplastic ependymoma,” doctors now classify ependymomas by where they arise (supratentorial brain, posterior fossa, or spinal cord) and by their molecular features (for example, ZFTA-fusion, YAP1-fusion, PFA or PFB subgroup, or MYCN-amplified). The older “anaplastic” label is discouraged, but in simple terms it corresponds to the higher-grade, more aggressive ependymomas in the modern system. PMC+2PMC+2

An anaplastic ependymal tumor is a fast-growing cancer that starts from ependymal cells, the lining cells of the brain’s ventricles and the spinal cord’s central canal. Historically, “anaplastic ependymoma” meant WHO grade 3 ependymoma. Since the 2021 WHO CNS5 update, the term “anaplastic” is largely retired; pathologists now diagnose “ependymoma” and assign a CNS WHO grade (2 or 3) within specific site- and molecularly-defined types (for example: supratentorial ZFTA-fusion positive, supratentorial YAP1-fusion positive, posterior fossa group A [PFA], posterior fossa group B [PFB], and spinal types including MYCN-amplified). In everyday words, the tumor’s “aggressiveness” is reflected by grade 3 features, but its official name depends on location and key genetic changes. PMC+2PMC+2

This newer system helps doctors predict behavior and choose tests and treatments more accurately, because tumors that look similar under the microscope can act very differently depending on their molecular subtype. For example, posterior fossa PFA ependymomas (mostly in younger children) usually behave more aggressively than PFB, and supratentorial ZFTA-fusion tumors generally act more aggressively than YAP1-fusion ones. PMC+1

---

Other names

• Anaplastic ependymoma (older WHO grade 3 term).

• Grade 3 ependymoma (generic, older way).

• Posterior fossa ependymoma, PFA (grade 2 or 3) — often the biologically “high-risk” posterior fossa form in children.

• Supratentorial ependymoma, ZFTA-fusion–positive — many cases historically called “anaplastic.”

• Supratentorial ependymoma, YAP1-fusion–positive — typically less aggressive than ZFTA-fusion.

• Spinal ependymoma, MYCN-amplified — a molecularly defined, aggressive spinal form.
  These names fit the 2021 WHO system and replace routine use of the single word “anaplastic.” PMC+1

---

Types

1) Supratentorial ependymoma, ZFTA-fusion–positive.
Arises in the upper brain (above the tentorium); driven by fusions involving the ZFTA gene (formerly RELA). These tend to be more aggressive and often align with what used to be called “anaplastic.” Frontiers

2) Supratentorial ependymoma, YAP1-fusion–positive.
Also in the upper brain, but with YAP1 fusions; overall it shows a more favorable course than ZFTA-fusion disease, especially in young children. ScienceDirect

3) Posterior fossa ependymoma, PFA.
Located around the fourth ventricle/cerebellum region, usually in infants and younger children. PFA tumors typically lack H3 K27-trimethylation (H3K27me3) and often carry a poorer prognosis than PFB. PMC

4) Posterior fossa ependymoma, PFB.
More often in older children/adolescents; biologically less aggressive than PFA on average. PMC

5) Spinal ependymoma (conventional).
Arises in the spinal cord; in adults it is the most common ependymoma site. A subset shows MYCN amplification, which marks an aggressive spinal subtype. Frontiers

6) Spinal ependymoma, MYCN-amplified.
A recently recognized molecular entity associated with high-grade behavior. Frontiers

(Note: myxopapillary ependymoma and subependymoma are distinct, usually lower-grade entities and are not what “anaplastic ependymal tumor” referred to.) Cancer.gov

---

Causes

Important context: for most people, there is no single preventable cause. Many items below are molecular drivers or risk associations that help explain why these tumors develop or behave aggressively. Where evidence is limited, I say so plainly.

1. Cell of origin: ependymal cell transformation.
   Ependymomas arise from ependymal lineage cells that line CSF pathways in brain and spinal cord. When these cells acquire cancerous changes, a tumor can form. Cancer.gov

2. ZFTA (RELA) gene fusions (supratentorial).
   These fusions activate pathways that drive tumor growth in supratentorial ependymomas—historically many of the “anaplastic” cases. Frontiers

3. YAP1 gene fusions (supratentorial).
   An alternative driver; tumors often behave more indolently than ZFTA-fusion tumors. ScienceDirect

4. Loss of H3K27me3 (PFA subgroup).
   A hallmark epigenetic pattern in PFA ependymoma associated with a more aggressive course. PMC

5. Chromosome 1q gain.
   Copy-number gain of 1q is one of the most established adverse biological markers across ependymoma groups, especially PFA. It correlates with poorer outcomes (a driver of risk more than a causative exposure). PMC+1

6. Chromosome 6q loss (especially at recurrence in PFA).
   Another copy-number event linked to high-risk biology in recurrent PFA disease. Children’s Hospital Colorado

7. MYCN amplification (aggressive spinal form).
   Amplification of MYCN defines a high-grade spinal ependymoma subtype with aggressive behavior. Frontiers

8. NF2 gene inactivation / Neurofibromatosis type 2 (NF2).
   People with NF2 carry a higher risk of ependymomas—particularly spinal—and their tumors often harbor NF2 alterations. American Cancer Society+1

9. Developmental/age-related epigenetic context.
   PFA tumors concentrate in very young children, suggesting that the developmental state of the posterior fossa tissue helps permit tumor formation when other hits occur. PMC

10. Tumor microenvironment along CSF pathways.
    Proximity to ventricles and CSF flow is a biologic context, facilitating both growth patterns and potential spread along CSF. (Spread is not a cause of formation, but CSF adjacency is intrinsic to the ependymal cell origin.) PMC

11. Other, less common copy-number changes.
    Besides 1q gain and 6q loss, group-specific chromosomal imbalances contribute to tumor biology and risk, though patterns vary by subgroup. PMC

12. Gene expression programs tied to ZFTA/YAP1 pathways.
    The fusion genes rewire transcriptional programs that sustain growth and survival. Frontiers

13. Epigenetic dysregulation beyond H3K27me3.
    Genome-wide methylation “signatures” help define ependymoma types and likely participate in tumor behavior. PMC

14. Rare germline predisposition beyond NF2 (limited evidence).
    Most ependymomas are not strongly tied to inherited syndromes beyond NF2; rare reports exist but are not well established. (Transparency note.) Cancer Therapy Advisor

15. Prior craniospinal irradiation (very rare secondary tumors).
    Radiation can, rarely, lead to secondary CNS neoplasms; this is reported broadly in neuro-oncology but is not a common, proven cause for ependymoma specifically. (Transparency note.) Cancer.gov

16. Anatomic site–specific biology.
    Posterior fossa, supratentorial, and spinal compartments have different developmental programs—this helps explain why the same histology behaves differently by site. PMC

17. Surgical seeding risk during resection (spread, not origin).
    Careless handling can theoretically seed tumor cells into CSF, which is why meticulous technique matters; this does not cause the tumor but can worsen its course. Spandidos Publications

18. Tumor cell adhesion markers (e.g., L1CAM with RELA/ZFTA).
    Some aggressive supratentorial tumors show L1CAM immunoreactivity linked to ZFTA fusions, reflecting altered cell adhesion and behavior. PMC

19. Angiogenic signaling around vessels.
    Perivascular growth patterns (pseudorosettes) suggest tumor–vessel interactions that support survival and spread within tissue. (Pattern is well described; exact causal pathways are under study.) Radiopaedia

20. Stochastic (chance) genetic/epigenetic events.
    For many patients, no risk factor is found; random DNA changes during cell division likely play a role—common in many childhood CNS tumors. (General PDQ background.) NewYork-Presbyterian

---

Symptoms

1) Headache that’s worse in the morning.
Raised pressure from blocked CSF flow can cause early-morning or positional headaches; vomiting may temporarily relieve the pressure. Radiopaedia

2) Nausea and vomiting.
These often accompany pressure buildup (hydrocephalus) from a posterior fossa tumor obstructing the fourth ventricle. Radiopaedia

3) Problems with balance or walking (ataxia).
Posterior fossa tumors can affect the cerebellum and brainstem pathways, leading to unsteady gait and clumsiness. ARRS InPractice

4) Double vision or other cranial nerve symptoms.
Brainstem compression or nerve involvement can cause diplopia, facial weakness, or swallowing difficulty. ARRS InPractice

5) Irritability, lethargy, or rapid head growth in infants.
In very young children, subtle behavior changes or increasing head size can be signs of hydrocephalus from a posterior fossa mass. Cancer.gov

6) Seizures.
Supratentorial (upper brain) tumors can trigger seizures because they irritate the brain cortex. Frontiers

7) Focal weakness or numbness.
Depending on where the tumor presses, a person may notice weakness in an arm/leg or sensory changes. Cancer.gov

8) Back pain.
Spinal ependymomas often cause persistent midline back pain that worsens with exertion or Valsalva. PubMed

9) Shooting leg pain or tingling (radiculopathy).
When tumor touches nerve roots, pain can radiate down a limb in a “nerve” pattern. PubMed

10) Bowel or bladder changes.
Spinal cord involvement can disrupt sphincter control, causing urgency, retention, or incontinence. PubMed

11) Neck stiffness or pain.
Cervical spinal tumors can cause neck pain, reduced range of motion, or shooting arm pain. PubMed

12) Dizziness and vertigo.
Posterior fossa tumors may affect vestibular pathways, leading to spinning sensations or imbalance. ARRS InPractice

13) Visual blurring from papilledema.
Raised intracranial pressure can swell the optic discs (papilledema), causing transient visual blur. Radiopaedia

14) Cognitive or personality changes.
Frontal or temporal lobe involvement from supratentorial tumors can alter attention, memory, or mood. Cancer.gov

15) “Drop metastasis” symptoms along the spine.
If tumor cells spread through CSF (“drop” spread), people can develop new back/leg pain, weakness, or sphincter changes away from the original site. PMC

---

Diagnostic tests

A) Physical exam

1) Full neurological examination.
Your clinician checks strength, sensation, reflexes, coordination, balance, and cranial nerves. Findings guide where to image (brain vs spinal cord) and track changes over time. Cancer.gov

2) Fundoscopic (eye) exam for papilledema.
Using an ophthalmoscope, the doctor looks for swollen optic discs—an important sign of raised intracranial pressure from obstructed CSF flow. Radiopaedia

3) Gait and coordination testing.
Simple bedside tasks (heel-to-toe walking, finger-to-nose, heel-to-shin) can reveal cerebellar or long-tract problems common with posterior fossa masses. ARRS InPractice

4) Spine-focused neurologic screening.
For suspected spinal disease: dermatomal sensory testing, motor strength by myotome, sphincter tone, and saddle sensation help localize a cord or root level. PubMed

B) Manual/bedside tests

5) Romberg test.
Standing with feet together (eyes open, then closed) screens position-sense and balance; instability can hint at posterior column or cerebellar issues when paired with other signs. ARRS InPractice

6) Straight-leg raise (for radicular pain).
Raising the leg stretches lumbar roots; shooting pain suggests nerve-root irritation from a spinal mass. This is only a screening clue; imaging confirms. PubMed

7) Cranial nerve bedside maneuvers.
Quick checks of eye movements, facial strength/sensation, corneal reflex, and swallow help recognize brainstem/cranial nerve involvement seen with fourth-ventricle tumors. ARRS InPractice

C) Laboratory and pathological tests

8) Surgical pathology (histology).
Diagnosis rests on tissue. Under the microscope, ependymomas classically show perivascular pseudorosettes (tumor cells arranged around a blood vessel) and sometimes true ependymal rosettes. High-grade tumors show brisk cell division (high Ki-67/MIB-1), necrosis, and microvascular proliferation. Radiopaedia+1

9) Immunohistochemistry (IHC).
Tumor cells often stain for GFAP (a glial marker) and show EMA in a dot-like/ring-like pattern; patterns help confirm ependymoma and exclude look-alikes. Loss of H3K27me3 supports a PFA subtype in posterior fossa tumors. PubMed+2PMC+2

10) DNA methylation profiling.
Modern centers use genome-wide methylation arrays to classify ependymomas into precise subtypes (PFA, PFB, ZFTA-fusion, etc.). This improves diagnostic accuracy when histology is ambiguous. PMC

11) Targeted molecular testing for fusions/amplifications.
Testing can detect ZFTA (RELA) or YAP1 fusions in supratentorial tumors and MYCN amplification in spinal tumors—findings that carry prognostic value. Frontiers

12) CSF cytology (select cases).
Examining cerebrospinal fluid for tumor cells can help stage disease if leptomeningeal spread is suspected; it is usually done after imaging and only when safe (LPs are contraindicated in many posterior fossa masses because of herniation risk). PMC+1

13) Routine blood tests (supportive, not diagnostic).
CBC and chemistry panels don’t diagnose ependymoma but assess overall health pre-op, guide chemo-/radiotherapy readiness, and monitor complications. (Oncology practice standard; general.) Cancer.gov

D) Electrodiagnostic tests

14) EEG (when seizures occur).
For supratentorial tumors with seizures, EEG documents epileptiform activity, helps classify seizures, and guides anti-seizure treatment. (General neuro-oncology practice.) Cancer.gov

15) Intraoperative neurophysiologic monitoring (spinal surgery).
SSEPs and MEPs are checked during spinal tumor surgery to protect cord tracts and reduce postoperative deficits. PMC

E) Imaging tests

16) MRI of the brain with and without contrast.
This is the key test for intracranial disease. Ependymomas often appear as heterogeneous masses that can have cysts, calcification, hemorrhage, and variable enhancement; posterior fossa tumors often arise from the floor of the fourth ventricle and may extend through the foramina. Diffusion-weighted imaging and perfusion can add clues; MR spectroscopy may show elevated choline. Cureus+3PMC+3Radiopaedia+3

17) MRI of the entire spine with contrast.
Even if the main tumor is in the brain, MRI of the whole spine looks for CSF “drop” metastases; for primary spinal tumors, full-length imaging defines extent and operative planning. LWNO

18) Craniospinal MRI for staging.
When spread is suspected, craniospinal axis imaging (brain + whole spine) is standard to detect leptomeningeal disease and to plan radiation fields if needed. Medscape

19) CT head (when urgent).
CT is faster and shows hydrocephalus or calcifications but is less detailed than MRI for tumor definition; it’s useful in emergencies and surgical planning. PMC

20) Advanced MRI techniques (as available).
Diffusion, perfusion, and MR spectroscopy can help distinguish ependymoma from other posterior fossa tumors (like medulloblastoma) and provide noninvasive hints about tumor grade and cellularity. Cureus+1

Treatment overview

For both children and adults, the most important treatment is maximal safe surgical removal. If any tumor remains—or if features indicate higher risk—precise local radiotherapy (photon or proton) is usually recommended, particularly in children older than about 12–18 months and in adults. The role of chemotherapy is limited and mainly considered in clinical trials, recurrent disease, very young children (to delay radiation), or when surgery/radiation aren’t possible. PMC+3PMC+3PubMed+3

Non-pharmacological treatments (therapies & others)

1. Maximal safe resection (first-line): Removing as much tumor as safely possible improves control and survival. Repeat surgery may be considered for recurrence. PMC+1

2. Conformal radiotherapy (photon IMRT): High-precision radiation to the tumor bed while sparing healthy brain; now standard after surgery in most pediatric intracranial cases. PMC

3. Proton beam therapy: Similar tumor control with potentially less dose to normal brain/spine; used widely in children. Oxford Academic

4. Stereotactic radiosurgery (selected recurrences): Focused “boost” or salvage for small residual/recurrent foci in carefully chosen cases. SpringerLink

5. CSF diversion (shunt or ETV): Relieves hydrocephalus caused by blocked CSF flow; treats headaches and vomiting. Cancer.gov

6. Neuro-rehabilitation (PT/OT): Restores balance, gait, strength, and daily independence after brain/spinal surgery and radiation. ASCO Publications

7. Speech-language therapy: Helps speech, swallowing, and cognitive-communication, especially with posterior fossa/brainstem involvement. ASCO Publications

8. Neuropsychology & school accommodations: Memory/attention support, IEP/504 plans, and cognitive rehab to improve learning and quality of life. ASCO Publications

9. Psychosocial counseling & mindfulness/CBT for anxiety/pain: Evidence supports exercise and behavioral strategies to reduce fatigue and distress during/after cancer treatment. ASCO Publications+1

10. Exercise (aerobic + resistance) during and after treatment: Improves fatigue, physical function, and survivorship outcomes; tailor to safety with your team. ASCO Publications+1

11. Nutrition counseling: Focus on balanced, plant-forward eating to maintain strength, weight, and healing (see diet section below). ACS Journals

12. Vestibular therapy: For dizziness/imbalance from posterior fossa disease or treatment. ASCO Publications

13. Vision rehabilitation: For diplopia or visual field defects after tumor or surgery. ASCO Publications

14. Hearing rehabilitation: Early audiology input and devices if needed after posterior fossa therapy. ASCO Publications

15. Pain self-management training: Post-operative/neuropathic strategies, pacing and posture education; integrate with medical management. ASCO Publications

16. Seizure safety education: Rescue plans, sleep hygiene, and trigger avoidance where seizures occur. Cancer.gov

17. Fatigue management programs: Activity-rest cycling, graded activity, sleep strategies. ASCO Publications

18. Fertility preservation counseling: Timing matters before RT/chemo in adolescents/young adults. ASCO Publications

19. Palliative care early integration: Symptom control (pain, nausea, mood) and goal setting—not limited to end-of-life. ASCO Publications

20. Clinical trial navigation: Many advances come through trials; ask about options at diagnosis and at recurrence. Cancer.gov

Why radiotherapy features prominently: In modern pediatric series (e.g., ACNS0121), timely conformal radiotherapy after surgery is linked to better event-free and overall survival; chemotherapy alone rarely matches these outcomes. PMC+1

Medicines used

Important: There is no universally effective “standard” chemotherapy for ependymoma like there is for some other cancers. Drugs are used selectively for recurrence, for very young children to delay radiation, or within clinical trials. Below are key agents/regimens clinicians consider—evidence is mixed and often from small studies. Doses here are typical reference ranges; your team will individualize. PMC+1

1. Temozolomide (TMZ; oral alkylator): Often used at recurrence; adult series show responses and disease control in chemo-naïve patients. Typical dosing: 150–200 mg/m² daily ×5 days every 28 days. Common side effects: fatigue, low blood counts, nausea. Evidence in ependymoma is modest but supportive in select adults. PMC+1

2. TMZ + Lapatinib (EGFR/HER2 TKI): Phase II adult trial showed objective responses and prolonged control in recurrent ependymoma across grades 1–3. Dose: lapatinib 1250 mg daily continuously + dose-dense TMZ schedules. Side effects: diarrhea, rash, cytopenias. Considered a salvage option. PubMed+1

3. Carboplatin (platinum): Used alone or with other agents at recurrence; myelosuppression and nausea are common. Dosed by AUC (e.g., AUC 4–5 q4w). PMC+1

4. Bevacizumab (anti-VEGF antibody): Sometimes added for recurrent disease to reduce edema and enhance radiographic response; risks include hypertension, bleeding, and wound-healing delays. PMC+1

5. Cisplatin ± Etoposide (platinum + topoisomerase inhibitor): components of pediatric regimens trying to delay RT in infants; nephro/oto-toxicity (cisplatin) and marrow suppression are key risks. Cancer.gov

6. Ifosfamide/Cyclophosphamide (alkylators): Used in combinations for recurrent pediatric disease; watch for marrow suppression, hemorrhagic cystitis (mesna used with ifosfamide). Cancer.gov

7. Vincristine (microtubule inhibitor): In infant protocols; neuropathy and constipation common. Cancer.gov

8. Topotecan (topoisomerase I inhibitor): Has been explored, including in combinations; myelosuppression and mucositis are typical. PubMed

9. Everolimus (mTOR inhibitor; oral): Tested in pediatric recurrent ependymoma; was well-tolerated but showed limited/no activity in PF-A tumors. Side effects include mouth sores and high lipids/glucose. PMC+1

10. Pazopanib (multi-TKI) and other TKIs: Occasionally considered in trials/compassionate settings for recurrent disease; hypertension, hand–foot syndrome, and liver enzyme elevations are typical. (Evidence in ependymoma remains limited.) Center for Cancer Research

11. Bevacizumab + Carboplatin (combination): Investigated as salvage; radiographic responses occur in some patients; risks combine those of each drug. PMC+1

12. Supportive neurologic medicines (context): Dexamethasone for edema (shortest effective time), antiemetics (ondansetron), and antiseizure medicines (levetiracetam) are common adjuncts—tailored to symptoms. (These support care; they don’t treat the tumor itself.) Cancer.gov

Bottom line on medicines: Surgery + precise radiotherapy remain the backbone; drugs are individualized, often in trials or at recurrence. PMC+1

Dietary molecular supplements

There is no supplement proven to shrink ependymoma. The best-supported advice for people living with cancer is a healthy dietary pattern and physical activity. If you consider supplements, discuss them with your team to avoid interactions. ACS Journals+1

• Vitamin D: Many patients have low levels; repletion to normal may support bone/muscle health and general wellness. Avoid excess (upper safe limit 4000 IU/day for adults without medical supervision). Cancer.gov

• Omega-3 fatty acids (fish oil): May help with triglycerides/inflammation; check bleeding risk if on bevacizumab or before surgery. ACS Journals

• Multivitamin at RDA doses: Reasonable if diet is limited; mega-dosing isn’t helpful and can be harmful. ACS Journals

• Fiber (psyllium/foods): Supports bowel regularity, especially with constipating meds. ACS Journals

• Protein supplementation (whey/pea) if intake is poor: Helps maintain lean mass during therapy. ACS Journals

• Vitamin C/folate from foods: Observational links with brain-tumor risk exist, but causality is unproven—prefer food sources. PMC

• Mushroom extracts (shiitake/maitake): Popular, but clinical antitumor evidence is lacking; use caution with immunotherapies. The Brain Tumour Charity

• Probiotics/fermented foods: May help GI comfort; confirm safety if neutropenic. ACS Journals

• Magnesium (sleep/constipation/muscle cramps): Use standard doses; watch for diarrhea and interactions. ACS Journals

• Green-tea (EGCG) beverages: Generally safe in moderation; supplement pills can interact with drugs—avoid high-dose extracts. ACS Journals

Immunity-booster / regenerative / stem-cell” drug

There are no approved stem-cell or “immune-booster” drugs that cure ependymoma. Experimental immunotherapies exist in early trials:

• HER2-directed CAR-T cells: Early pediatric brain-tumor trials include ependymoma; aim is to teach T-cells to attack tumor cells expressing HER2. Dosing and schedules are protocol-specific; risks include cytokine-release syndrome and neurotoxicity, managed in expert centers. ClinicalTrials.gov+1

• B7-H3-targeted CAR-T (research): Another brain-tumor target now being explored; still early phase for ependymoma. PMC

• Dendritic-cell vaccines: Small pediatric series show feasibility and occasional durable survivors; still investigational, given as protocol-defined vaccine courses. PMC

• PARP-inhibitor combinations (e.g., olaparib+TMZ): Preclinical/early clinical signals in pediatric brain tumors, with isolated case reports; not standard. PMC+1

• mTOR-pathway drugs (everolimus): Tested in recurrent ependymoma with little activity in PF-A; primarily a negative finding guiding future research. PubMed

• Multi-antigen or intraventricular CAR-T approaches: Ongoing trials are evaluating safety and dosing in CNS tumors including ependymoma; strictly within research settings. Seattle Children’s

---

Surgeries

1. Posterior fossa craniotomy/craniectomy (brainstem/cerebellar tumors): Surgeon accesses the tumor at the skull base to remove as much as safely possible; goal is gross total resection to improve control and survival. PMC

2. Supratentorial craniotomy (cerebral hemisphere tumors): Navigational and mapping tools guide safe removal near language/motor areas; complete removal can reduce the need for additional therapy. SpringerLink

3. Spinal laminectomy/laminoplasty (spinal tumors): Opens the spine to remove intramedullary tumors; neuro-monitoring helps protect function. Oxford Academic

4. Re-resection at recurrence: Considered if the tumor comes back and location allows; can improve local control and delay/optimize further treatments. SpringerLink

5. CSF diversion (VP shunt or endoscopic third ventriculostomy): Treats hydrocephalus caused by CSF blockage, relieving pressure symptoms. Cancer.gov

Prevention tips

Primary prevention is limited—most ependymomas aren’t caused by changeable lifestyle factors. Still, general cancer-prevention and survivorship guidance helps overall health and may improve tolerance of therapy:

• Keep a healthy weight and be as active as safely possible.

• Aim for 150–300 min/week of moderate activity plus 2+ days/week of strength work.

• Eat a plant-forward pattern (vegetables, fruits, whole grains, legumes).

• Limit processed meats, red meats, added sugars, and ultra-processed foods.

• Don’t smoke; avoid secondhand smoke.

• Limit alcohol (or avoid).

• Manage sleep and stress.

• Keep vaccinations up to date (flu/COVID, etc.) as advised by your team.

• Use radiation and imaging only when medically necessary (general principle).

• Seek genetic counseling if there’s a strong family history or features suggesting NF2. ACS Journals+2American Cancer Society+2

When to see a doctor

Seek urgent care for: persistent morning headaches with vomiting; new seizures; sudden severe headache; rapidly worsening balance or weakness; new double vision; inability to wake/alert a child; loss of bladder/bowel control; high fever with severe neck stiffness. Book a prompt visit for: progressive headaches, school decline, new clumsiness, back pain with leg symptoms, or any new neurologic sign. Cancer.gov

What to eat (and what to avoid)

Emphasize: vegetables and fruits; whole grains (oats, brown rice); legumes (beans, lentils); nuts/seeds; fish and modest lean poultry; dairy/yogurt if tolerated; olive/plant oils; enough fluids; small frequent meals during treatment; protein at each meal/snack to maintain muscle. Limit/avoid: processed meats, excess red meat, sugary drinks, highly processed snacks/desserts, trans-fat foods, binge alcohol, and high-dose unproven supplements. Tailor for nausea, constipation, or appetite loss with your dietitian. ACS Journals+1

Frequently asked questions

1. Is “anaplastic ependymoma” still a diagnosis? The term is mostly retired; doctors now specify ependymoma type by site/molecular class and assign grade (2 or 3). PMC

2. What’s the main treatment? Maximal safe surgery, then focused radiotherapy in most brain cases. PMC+1

3. Does chemotherapy work? Limited role; used mainly in trials, at recurrence, or in infants to delay RT. Cancer.gov

4. Is proton therapy better? Similar control with potential to spare normal tissues—especially helpful in children. Oxford Academic

5. Will my child need spinal MRI/LP? Yes, staging often includes brain + spine MRI and CSF cytology (LP after safe imaging). Medscape

6. What is PFA vs PFB? Two molecular groups of posterior fossa ependymoma; PFA tends to behave more aggressively. PMC

7. What is ZFTA or YAP1 fusion? Key genetic changes that define many supratentorial tumors. PMC

8. What’s the chance of cure? Strongly depends on complete resection, tumor type, and age; 5-year survival in modern pediatric series can exceed 70–80% in some groups. Your team will personalize estimates. PMC

9. Can it spread? It can seed within CSF pathways; whole-neuroaxis imaging and CSF checks are used. Cancer.gov

10. What if it comes back? Options include re-operation, focused re-irradiation, and clinical trials/selected drug regimens. SpringerLink

11. Are “immune boosters” helpful? No supplement is proven to treat ependymoma; experimental immunotherapies exist only in trials. ClinicalTrials.gov+1

12. Should we travel for proton therapy? Discuss benefits/risks/logistics with your team—especially for young children. Oxford Academic

13. Do diet and exercise matter? Yes—for strength, fatigue, and overall health; follow cancer-survivorship nutrition and activity guidance. ACS Journals+1

14. Where can I read clinician-level details? See NCI PDQ (pediatric/adult), EANO guidelines, and NCCN CNS Cancers. Cancer.gov+2PMC+2

15. How do we find trials? Ask your center and search NCI’s clinical trials pages for “ependymoma.” Cancer.gov

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.